A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
This research study is looking into a new medication, DNL593, for people with a specific type of frontotemporal dementia (FTD-GRN). It's a phased study designed to carefully check the drug's safety, how well people tolerate it, and how it moves through and affects the body. Initially, healthy volunteers will receive single doses. Then, people living with FTD-GRN will take multiple doses over several months, with some receiving a dummy drug (placebo) for comparison. The goal is to understand if DNL593 could be a future treatment option for this condition, with an option for continued treatment after the main study.
Överblick
Vad handlar denna studie om?
This study is investigating a new medicine called DNL593, which could potentially help people with a specific type of frontotemporal dementia (FTD). FTD is a form of dementia that mainly affects the front and side parts of the brain, leading to changes in personality, behaviour, and language. This particular study focuses on FTD linked to a genetic change called a GRN mutation.
The study is split into different stages to carefully check the new medicine. First, healthy volunteers will receive a single dose of DNL593 to see how their bodies handle it and to check for any immediate side effects. After that, people diagnosed with FTD-GRN will take the medicine for a longer period. Some will receive DNL593, while others will get a placebo – an inactive substance that looks just like the real medicine. This allows researchers to compare the effects and determine if DNL593 is genuinely making a difference.
Understanding how a new medicine works, what doses are safe, and its potential benefits and risks is a crucial part of developing new treatments. This study aims to gather this vital information for DNL593, moving it closer to potentially becoming a treatment option for FTD-GRN in the future. Participants who complete the main part of the study may also have the option to continue receiving the medicine in an extended follow-up period.
Viktiga punkter
- This study evaluates a new drug, DNL593, for frontotemporal dementia linked to the GRN gene.
- It aims to check the drug's safety, how it's handled by the body, and its potential effects.
- Healthy volunteers are involved first, followed by people with FTD-GRN.
- Some participants will receive a dummy drug (placebo) for comparison.
- Participation involves regular clinic visits for health checks and tests.
- The study includes an optional extended treatment period for eligible individuals.
Vem kan vara berättigad?
To join this study, specific requirements must be met. For the first part, healthy men and women (who are past menopause or have had a hysterectomy/sterilisation) between 18 and 55 years old are needed. They also need to have a body mass index (BMI) within a certain range.
For the second part of the study, which involves people with frontotemporal dementia (FTD-GRN), participants must be men or women (who are past menopause, sterilised, or using highly effective contraception) between 18 and 80 years old, with a similar BMI requirement. Importantly, they must have a confirmed GRN genetic mutation, which is linked to this specific form of FTD.
However, some conditions would prevent someone from joining. This includes a history of many serious health issues such as significant heart, lung, kidney, liver, or neurological problems (like a recent stroke or seizures). Also, anyone with a history of most cancers, pregnant or breastfeeding women, or those with significant allergies would not be able to participate. The research team will carefully check everyone's medical history to ensure their safety in the study.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du mellan 18 och 80 år gammal?
- Do you have a diagnosis of frontotemporal dementia with a confirmed GRN genetic mutation?
- Kan du delta i regelbundna klinikbesök?
- Do you have any serious underlying health conditions like significant heart, kidney, or liver disease?
Vad innebär deltagande?
If you take part in this study, what you do will depend on which part you are in. Healthy volunteers in Part A will receive a single dose of the study medicine (DNL593) or a placebo, requiring several visits for health checks and blood tests. Participants in Part B, who have FTD-GRN, will receive multiple doses of DNL593 or a placebo over approximately 25 weeks (about 6 months). This will involve regular visits to the clinic for assessments, including health checks, memory and thinking tests, and blood samples, to monitor the medicine's effects and your general health. There will also be follow-up calls or visits after the main treatment period.
For those who complete Part B and meet certain criteria, there's an optional Part C, where you could continue receiving DNL593 for an additional 18 months. This optional extension would also involve regular clinic visits and health monitoring. The total duration of participation varies depending on the part you are in, and whether you choose to enter the optional extension.
Potentiella risker och fördelar
Platser (26)
- Universitetet i Kalifornien San FranciscoVerifierat postnummerSan Francisco, USA
- John Hopkins UniversitetVerifierat postnummerBaltimore, USA
- Hospital of the University of PennsylvaniaVerifierat postnummerPhiladelphia, USA
- University of AntwerpVerifierat postnummerAntwerpen, Belgien
- UZ LeuvenVerifierat postnummerLeuven, Belgien
- L2IP - Instituto de Pesquisas Clinicas LTDAVerifierat postnummerBrasília, Brasilien
- Faculdade de Medicina Da Universidade de São PauloVerifierat postnummerSão Paulo, Brasilien
- Hospital Universitario San IgnacioVerifierat postnummerBogotá, Colombia
- Grupo de Neurosicencias de la Universidad de AntioquiaVerifierat postnummerMedellín, Colombia
- Fakultni nemocnice v MotoleVerifierat postnummerPrag, Tjeckien
- CHU de NantesVerifierat postnummerNantes, Frankrike
- CHU RouenVerifierat postnummerRouen, Frankrike
Vanliga frågor
What is Frontotemporal Dementia (FTD-GRN)?
FTD-GRN is a specific type of dementia that affects brain areas responsible for personality, behaviour, and language, caused by changes in the GRN gene.
Vad är en placebo?
A placebo is an inactive substance that looks exactly like the study medicine but contains no active drug. It helps researchers compare the real effects of the medicine.
Kommer jag att veta om jag får den riktiga medicinen eller placebo?
No, this is a 'double-blind' study, meaning neither you nor the study team will know who is receiving the actual medicine (DNL593) and who is getting the placebo until the study is over.
What is the study medicine, DNL593?
DNL593 is a new investigational medication being tested to see if it can be a safe and effective treatment for specific forms of frontotemporal dementia.
Can I leave the study at any point?
Yes, you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.